Literature DB >> 8732994

Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.

W K Oelkers1.   

Abstract

Endogenous 17 beta-estradiol (E2) and low parenteral doses of exogenous E2 are vasodilators. High dose estrogens, especially ethinylestradiol (EE) and mestranol, stimulate the synthesis of hepatic proteins including coagulation factors, sex hormone binding globulin, and angiotensinogen (Aogen). In the steady state, high plasma levels of Aogen produce only a very small increase of angiotensin II (AII) and plasma renin activity, because AII inhibits the secretion of renin and lowers plasma renin concentration. However, the increase in AII is sufficient for a slight reduction in renal blood flow and a slight increase in exchangeable sodium and blood pressure; in susceptible women, blood pressure may rise considerably. Effects of estrogens on the brain may also be involved in blood pressure changes. Endogenous progesterone is a mineralocorticoid receptor antagonist. Endogenous or exogenous progesterone leads to sodium loss and a compensatory increase in renin secretion, plasma renin activity, AII, and plasma aldosterone, e.g. in the second half of the menstrual cycle. Synthetic progestogens are commonly devoid of the mineralocorticoid receptor antagonistic effect of progesterone, and some are weak estrogen receptor agonists. Combined use of EE and synthetic progestogens may therefore enhance estrogen effects on body sodium and blood pressure. A new progestogen (Drospirenone) with an antimineralocorticoid effect like that of progesterone is described that slightly lowers body weight and blood pressure in a contraceptive formulation together with EE. An almost ideal oral contraceptive would be progestogen like Drospirenone together with a low dose natural estrogen that does not stimulate Aogen synthesis. Since most oral formulations for postmenopausal estrogen replacement also stimulate hepatic protein synthesis (including Aogen) to some extent, the transdermal route of E2 application for contraceptive purposes should also be investigated, since it has reduced potential for undesirable side effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732994     DOI: 10.1016/0039-128x(96)00007-4

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  52 in total

Review 1.  Effects of gender on the renin-angiotensin system, blood pressure, and renal function.

Authors:  Amrit K Kang; Judith A Miller
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

2.  In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.

Authors:  Taofeek K Owonikoko; Maria E Fabucci; Philip R Brown; Nighat Nisar; John Hilton; William B Mathews; Hayden T Ravert; Paige Rauseo; Kathryn Sandberg; Robert F Dannals; Zsolt Szabo
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

Review 3.  Physiological responses to the menstrual cycle: implications for the development of heat illness in female athletes.

Authors:  Susan A Marsh; David G Jenkins
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

4.  Mineralocorticoid substitution in pregnant Addisonian women.

Authors:  W Oelkers
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

5.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

6.  Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.

Authors:  Fan Guang-Sheng; Bian Mei-Lu; Cheng Li-Nan; Cao Xiao-Ming; Huang Zi-Rong; Han Zi-Yan; Jing Xiao-Ping; Li Jian; Wu Shu-Ying; Xiong Cheng-Liang; Xiong Zheng-Ai; Yue Tian-Fu
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.

Authors:  Thomas Simon O'Hagan; Whitney Wharton; Patrick Gavin Kehoe
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  Drospirenone, a new progestogen, for postmenopausal women with hypertension.

Authors:  Madhavi Mallareddy; Vladimir Hanes; William B White
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies.

Authors:  Jane Morley Kotchen; Theodore A Kotchen
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

10.  Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats.

Authors:  Viorica Braniste; Aurore Jouault; Eric Gaultier; Arnaud Polizzi; Claire Buisson-Brenac; Mathilde Leveque; Pascal G Martin; Vassilia Theodorou; Jean Fioramonti; Eric Houdeau
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.